Cellectis and Cytovia in US$760m licence d...Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies. more ➔
Cellink AB acquires Ginolis Oy for €70mCellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries. more ➔
Rentschler Biopharma launches gene therapy...CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd. more ➔
InteRNA Technologies secures €18.5m in S...MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company. more ➔
German Health Ministry to invest €6.2bn...The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines. more ➔
V-Bio Ventures launches second fund at €...V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU. · more ➔
Abingworth raises US-$465m for new life sc...The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies. more ➔
Two companies aim for 2nd-gen COVID vaccin...As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines. more ➔
Rentschler Biopharma to produce 100m doses...German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV. more ➔
Italian Enthera Pharma raise €35m in Ser...Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the companys investor syndicate. more ➔
